Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced on Monday that its experimental drug, when combined with Novo ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron Pharmaceuticals has signed a new licensing agreement with Hansoh Pharmaceuticals Group to develop and sell its weight loss therapy outside of China.